GeneCentric

GeneCentric develops cancer diagnostics that translate tumor biology complexity into actionable clinical tools, featuring the PurIST pancreatic cancer test commercialized and clinically validated with Tempus, and the ExpressCT liquid biopsy technology that captures quantitative gene expression measurements directly from cfDNA sequencing data. ExpressCT is a proprietary fragmentomics technology and software layer that unlocks gene expression dimensions from routinely generated NGS data, enabling simultaneous collection of DNA alterations alongside gene expression biomarkers including ER status, HER2 expression, and molecular subtypes. The company presented three AACR 2026 posters demonstrating ExpressCT liquid classifiers for ER, HER2, and HR status in breast cancer, and launched ExpressCT Rewind to unlock gene expression insights from existing liquid biopsy DNA sequencing data. GeneCentric's Cancer Subtype Platform identifies biologic subtypes through integrated tumor genomics analysis, with the first-generation Lung Subtyping Predictor classifying tumors into squamous and non-squamous subtypes. Founded in 2011 and headquartered in Durham, North Carolina, the company has raised approximately $26.9M in Series C funding. GeneCentric differentiates itself through over a decade of research bringing gene expression into liquid biopsy workflows without requiring additional sequencing infrastructure.

Oncology > In-Vitro Diagnostic Tests > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA